alliant energy forgot password
Leave a comment

selecta biosciences stock forecast

Selecta Biosciences does not have a long track record of dividend growth. About the Selecta Biosciences, Inc stock forecast.

Sign-up to receive the latest news and ratings for SELB and its competitors with MarketBeat's FREE daily newsletter.Selecta Biosciences' stock was trading at $3.09 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization.

Selecta Biosciences, Inc. has license and collaboration agreements with Spark Therapeutics, Massachusetts Institute of Technology, Shenyang Sunshine Pharmaceutical Co., Ltd., and BIND Therapeutics, Inc.; and a strategic partnership with Asklepios BioPharmaceutical, Inc. for the development, manufacture, and commercialization of targeted therapeutics for adeno-associated virus gene therapies in the areas of high medical need. One share of SELB stock can currently be purchased for approximately $2.68.Selecta Biosciences has a market capitalization of $287.14 million and generates $6.68 million in revenue each year. Export data to Excel for your own analysis. Morningstar: © 2019 Morningstar, Inc. All Rights Reserved. As a group, equities research analysts forecast that Selecta Biosciences Inc will post -0.3 earnings per share for the current fiscal year. Company’s recent per share price level of $2.99 trading at -$0.2 or -7.43% at recent trade assigns it a market valuation of $261.59 Million. As a group, equities research analysts forecast that Selecta Biosciences Inc will post -0.3 earnings per share for the current fiscal year.

Most stock quote data provided by BATS. Its proprietary pipeline includes therapeutic enzymes, gene therapies, and other products and product candidates affected by undesired immune responses.

Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The stock has a market cap of $208.23 million, a PE ratio of -2.12 and a beta of 1.41. Find the latest Selecta Biosciences, Inc. (SELB) stock quote, history, news and other vital information to help you with your stock trading and investing. Company’s recent per share price level of $2.8 trading at $0.1 or 3.7% at ring of the bell on the day assigns it a market valuation of $244.97 Million.

Only 19.00% of the stock of Selecta Biosciences is held by insiders. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.According to analysts' consensus price target of $8.17, Selecta Biosciences has a potential upside of 204.7% from its current price of $2.68.Selecta Biosciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Selecta Biosciences has received 56.35% “underperform” votes from our community.Selecta Biosciences does not currently pay a dividend.Selecta Biosciences does not have a long track record of dividend growth.In the past three months, Selecta Biosciences insiders have not sold or bought any company stock.Only 19.00% of the stock of Selecta Biosciences is held by insiders.64.58% of the stock of Selecta Biosciences is held by institutions. Stock Information. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2019 and/or its affiliates. Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. "Selecta Biosciences' stock is owned by a variety of institutional and retail investors. In last trading session, Selecta Biosciences, Inc. (NASDAQ:SELB) saw 1,360,593 shares changing hands with its beta currently measuring 1.39. Stifel Financial Corp raised its position in Selecta Biosciences by 42.0% in the fourth quarter. In addition, the company engages in the development of gene therapy product candidates that are in preclinical development for rare inborn errors of metabolism, including SEL-302, a therapy program for the treatment methylmalonic academia; and SEL-313, a product candidate to treat ornithine transcarbamylase deficiency.

Marion Shalloe Now, New Zealand Bat Fly, Manfreds Copenhagen Menu, Mass Of Pure Magic Farm, Birmingham, Al Fire Stations, Revolution Hyaluronic Spray, Grasshopper Coding Answers, Reckless Love Lyrics Chords, Krishna Balram Movie, Dr Michael Wilson, Winona LaDuke Quotes, Orphans (1998 Full Movie), Poe Catalyst Calculator, Do You Believe In Magic American Pie, Power Outage 12020, Norovirus Canada 2019, Demi Moore Friends Episode, Warty Frogfish Care, W2s Height In Feet, Biking In Carcross Yukon, Punjabi Books Pdf, Raspberry Pi Music Player With Buttons, Papito Hayes Street, Energizer Rechargeable Batteries Coupons, Navy Football Roster 2014, Blade Brown - Daily Duppy Instrumental, Bathroom Window Curtains Ikea, Rachel Mcnally Instagram, Rashod Bateman Commits, Billo Rani Song, Colorado Wildfire Map 2020, Kent State Football 2012, Frank Sinatra Special, Doug Aldrich Whitesnake, Wheaton Weather Radar, Austria News Channel, Most Deadly Spider, Norwegian Kr To Usd, How K Asif Died, Pakurumo Meaning In English, Sacagawea Baby Daddy, Lorrie Arias The Swan, Oliver Elfman 2020, Used Tools On Craigslist, Places To Eat In Fairbanks Alaska, Gore Amusement Park Lexington, Tn, Tasmanian Devil Predators, Clavar La Espada, Minecraft Stone Beach, Wsl Big Wave Tour 2020, Ladybug Shadow Study, Nicholas King Nyc, Where Is The Obama Foundation Located, Neil Fitzmaurice Phoenix Nights,

selecta biosciences stock forecast